Lymphoma Research Foundation (LRF): CURE FL Awards (LOI)

Proposals shall focus on accelerating the development of cellular immunotherapy (e.g., CAR-T) and/ortargeted therapy for FL. In the long term, rational sequencing of these two classes is likely to be curative in a larger fraction of patients than either single approach. However, combination therapy for FL may not be an appropriate pursuit until more is known about optimal patient selection, mechanisms of resistance, and duration of effect of each distinct class. As such, programs that advance each therapeutic strategy separately with line of sight to a future combination approach will offer the greatest value to patients in both the near and long term.

Funding: up to $500,000 for up to 2 years.

https://www.theflf.org/the-flf-programme-cure-fl